177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8 Interventions:   Drug: Lutetium Lu 177-PSMA-617;   Biological: Pembrolizumab Sponsors:   University of California, San Francisco;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials